



## **VACCINE INDUSTRY LEADER GEORGE SIBER, M.D. JOINS VAXESS TECHNOLOGIES AS CHAIRMAN OF SCIENTIFIC ADVISORY BOARD**

***Former EVP and CSO at Wyeth Vaccines to guide development of company's proprietary vaccine stabilization technology***

CAMBRIDGE, Massachusetts—February 4th, 2014—Vaxess Technologies, Inc., an innovative life sciences company developing a novel vaccine stabilization technology, announced today that George Siber has joined the company as chairman of the scientific advisory board. Dr. Siber will play a key role in guiding the development of the company's silk protein-based technology. Vaxess's proprietary platform harnesses the unique properties of fibroin, a protein derived from naturally sourced silk fibers, to greatly improve the thermal stability of vaccine products. Heat-stable vaccines incorporating Vaxess's technology can alleviate cold-chain constraints on global vaccine access and reduce distribution costs.

Widely regarded as a leading authority on vaccines, Dr. Siber previously served as Executive Vice President and Chief Scientific Officer at Wyeth Vaccines, where he oversaw the development and launch of a number of widely distributed vaccines, including Prevnar (pneumococcal), Meningitec (meningococcal C conjugate vaccine) and FluMist (a live nasal influenza vaccine co-developed with MedImmune). Prior to Wyeth, he directed the Massachusetts Biologic Laboratories and was an associate professor at Harvard Medical School and Dana-Farber Cancer Institute. Dr. Siber's vast vaccine experience includes serving on numerous governmental and international committees, including at the World Health Organization the International Vaccine Institute, The European Commission's ADITEC Vaccine Consortium and the National Institutes of Health. He currently serves as Chief Scientific Officer of ClearPath Vaccines Company and also as director and/or scientific advisor to a number of other companies focused on developing vaccines and therapeutics for infectious diseases, including Genocea Biosciences, Selecta Biosciences, Vedantra Pharmaceuticals, and Visterra.

"I'm very excited to be working with this exciting technology" says George Siber, "because it has the potential to help us overcome one of the biggest hurdles in getting life-saving vaccines to the highest risk children living in developing countries with inadequate infrastructure".

"Vaxess's technology has the potential to dramatically improve the global vaccine landscape. Who better to lead the company's scientific efforts than a true pioneer who has brought a remarkable spate of innovations to the vaccine market over his forty year career" said Michael Schrader, CEO of Vaxess.

### About Vaxess Technologies

Founded in Boston, Massachusetts in 2012, Vaxess Technologies is pioneering a novel and proprietary stabilization technology for vaccines. The silk-based platform technology was developed in the labs of biomedical engineering professors David Kaplan and Fiorenzo Omenetto at Tufts University. For more information please visit the company website at [www.vaxess.com](http://www.vaxess.com) or send additional inquiries to [contact@vaxess.com](mailto:contact@vaxess.com).